Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Maas Enriquez

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2001
ESIMS--an ongoing clinical trial in secondary progressive multiple sclerosisO R Hommes, M Maas-Enriquez
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2005
Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five yearsJ Haas, M Maas-Enriquez, H-P Hartung
Journal of Thrombosis and Haemostasis : JTH|March 23, 2016
Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samplesS Kitchen, Y Katterle, H Beckmann, et al.
Pneumologie (Stuttgart, Germany)|March 13, 2003
[Difficulties in controlled inhalation of alpha 1-protease inhibitor]P Brand, M Maas Enriquez, T Meyer, et al.
Vox Sanguinis|October 29, 2000
Parvovirus B19 in idiopathic thrombocytopenic purpuraA Wehmeier, A M Eis-Hübinger, M Maas Enriquez, et al.
Archivos Del Instituto De Cardiologia De Mexico|September 1, 1986
[Ebstein's anomaly in infants]M Maas Enriquez, F Attie, L Muñoz Castellanos, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 22, 2017
Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limitD Garmann, S McLeay, A Shah, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 1, 2016
BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field studyS Kitchen, H Beckmann, Y Katterle, et al.
Journal of Thrombosis and Haemostasis : JTH|December 30, 2014
Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)K Kavakli, R Yang, L Rusen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2016
Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trialK Saxena, S Lalezari, J Oldenburg, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2001
ESIMS--an ongoing clinical trial in secondary progressive multiple sclerosisO R Hommes, M Maas-Enriquez
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2005
Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five yearsJ Haas, M Maas-Enriquez, H-P Hartung
Journal of Thrombosis and Haemostasis : JTH|March 23, 2016
Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samplesS Kitchen, Y Katterle, H Beckmann, et al.
Pneumologie (Stuttgart, Germany)|March 13, 2003
[Difficulties in controlled inhalation of alpha 1-protease inhibitor]P Brand, M Maas Enriquez, T Meyer, et al.
Vox Sanguinis|October 29, 2000
Parvovirus B19 in idiopathic thrombocytopenic purpuraA Wehmeier, A M Eis-Hübinger, M Maas Enriquez, et al.
Archivos Del Instituto De Cardiologia De Mexico|September 1, 1986
[Ebstein's anomaly in infants]M Maas Enriquez, F Attie, L Muñoz Castellanos, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 22, 2017
Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limitD Garmann, S McLeay, A Shah, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 1, 2016
BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field studyS Kitchen, H Beckmann, Y Katterle, et al.
Journal of Thrombosis and Haemostasis : JTH|December 30, 2014
Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)K Kavakli, R Yang, L Rusen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2016
Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trialK Saxena, S Lalezari, J Oldenburg, et al.
Pageof 2